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 We are trying to develop new Abs that can manipulate CD4 T cell responses and 
are usable as immunosuppressive agents.  To this end, we performed functional 
screening, in which we examined the effect of an Ab on the proliferation of mouse CD4 
T cells upon activation.  The Ab, LP5, inhibited the activation of CD4 T cells stimulated 
with an anti-CD3 Ab or peptide antigen.  The Ab alone had no stimulatory effect on 
CD4 T cells.  Biochemical experiments demonstrated that LP5 recognized the Thy-1 
(CD90) molecule.  Interestingly, the treatment of CD4 T cells with LP5 in vitro induced 
a temporary down-regulation of CD3 expression at the cell surface.  TCR molecules 
were also affected.  Other anti-CD90 Abs not inhibitory to CD4 T cell activation failed 
to induce a reduction in CD3.  Experiments in vitro revealed that the down-regulation 
caused by LP5 is due to an accelerated endocytosis of cell surface CD3.  In addition, it 
was shown that CD3 down-regulation before or in the early stages of T cell activation is 
critical for the induction of hyporesponsiveness.  Experiments in vivo showed that pre-
treatment of CD4 T cells with LP5 inhibited the rejection of semi-allogeneic bone 
marrow transplants.  Based on these observations, we propose that CD3 down-
regulation without any stimulatory activity against T cells could be one approach to 
inhibiting T cell activation, and CD90 would be an appropriate target. 
 








 regulatory T cells (Treg cells) have suppressive functions and play 
important roles in the maintenance of immune homeostasis [1,2].  It has been 
demonstrated that the manipulation of Treg cells in terms of number and function is 
useful in the prevention of autoimmune, inflammatory, and graft-versus-host diseases.  
To increase the number of Treg cells, purified Treg cells have been cultured with IL-2, 
dendritic cells (DCs) as APCs, and so on [3,4].  In some cases, to increase the 
suppressive function of Treg cells, it was required to pre-stimulate Treg cells with 
allogeneic cells before the in vivo transfer of Treg cells since freshly isolated Treg cells 
did not induce tolerance to bone marrow allografts [5-8].   It was also reported that very 
large numbers of non-specifically expanded Treg cells were required to inhibit bone 
marrow allograft rejection [9-11].  In other reports, Treg cells induced from non-Treg 
cells, so-called iTreg cells, were utilized in manipulating immune responses in vivo [12], 
although it remained unsolved how long iTreg cells are stable in their suppressive 
activity.  Thus, although Treg cells are an attractive cell population for regulating and 
manipulating immune responses, there are many complicated procedures involved in 
manipulating their numbers and functions.   
As one approach to manipulating immune responses, we have tried to establish 
monoclonal Abs exhibiting Treg cell-like suppressive activities.  Treg cells can suppress 
the activation of CD4 T cells stimulated with anti-CD3 Ab and/or Concanavalin A 
along with APC, allogeneic cells, and anti-CD3/anti-CD28 Ab-coated beads [3,13,14].  
However, in the presence of anti-GITR Ab, IL-4, or supernatant (SN) from DCs 
stimulated with LPS, Treg cells did not exhibit suppressive effects [15-17].  Based on 
these observations, we tried to establish mAbs that suppress the activation of CD4 T 
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cells in cultures in which Treg cells can exhibit suppressive activity, and at the same 
time, mAbs that cannot inhibit the activation of CD4 T cells in cultures in which Treg 
cells cannot exert suppressive activity.  Through the functional screenings of 
hybridomas, we have established some mAbs.   
In the present study, we have examined one of those mAbs, LP5, that had almost 
Treg cell-like properties under the conditions examined.  Biochemical experiments 
revealed that LP5 recognizes Thy-1 (CD90), a small GPI-anchored glycoprotein [18].  
In the mouse, CD90 is present on a variety of cell types including thymocytes and 
peripheral T cells.  More recently, CD90 has been used as a marker for lipid rafts in 
murine T cells [19].  Both stimulatory and negative regulatory roles for CD90 during T 
cell activation were suggested from studies using CD90-deficient mice or anti-CD90 
Abs [20-25].  In the process of analyzing the functions of LP5, we found that the Ab 
induces a temporary down-regulation of CD3/TCR expression.  It has been shown that 
TCR/CD3 complexes in T cells are internalized and recycled constitutively [26].  
Furthermore, once T cells are activated by an antigen, down-regulation of TCR/CD3 
expression at the cell surface is induced [27].  In contrast with this naturally occurring 
decrease, in this study, we demonstrated that the active down-regulation of CD3 is 
inducible by an anti-CD90 Ab, and the suppressive effect of LP5 against T cell-
activation is dependent on this decrease. 
 
Materials and Methods 
Animals.   
BALB/c (H-2
d
), CB17.scid, and CBF1 (H-2
dxb
) mice and Wistar rats were 
purchased from Japan SLC Inc. (Shizuoka, Japan) or Clea Japan (Tokyo, Japan).  
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DO11.10 mice, OVA peptide (323-339)-specific, MHC class II-restricted, TCR 






 background, were 
obtained from Taconic Farms (Germantown, NY).  All mice were maintained in a 
specific pathogen-free animal facility and treated in accordance with institutional 
guidelines for animal care.   
  
Tumors. 
 Meth A, EL-4, and RLm1 [BALB/c-derived radiation leukaemia, a gift from E. 
Nakayama (Okayama University, Japan)] [28] were used for the preparation of cell 
lysates. 
 
Cell preparation.   
Splenic cells were incubated at 5×10
7
/ml for 45 min at 37°C with the culture SN 
of hybridoma cells secreting anti-CD25 Ab (7D4), and rabbit complement diluted to a 
final concentration of 1:10 (Cedarlane Lab., Canada).  The treatment was repeated twice, 
and the resulting CD25
+
 cell-depleted cells were then incubated with magnetic beads 
conjugated with anti-CD4 (GK1.5) Ab (Miltenyi Biotec, Bergisch Gladbach, Germany), 




 T cells (positive 
selection).  The cells that passed through the magnetic column as non-binding cells 
were treated with mitomycin C, washed, and used as splenic APCs.  In some 
experiments, CD4 T cells were purified negatively with the use of a CD4
+
 T cell 
isolation kit (Miltenyi Biotec) (negative selection). 
 
Cell culture.   
  
 6 
CD4 T cells (1x10
4
/well) were stimulated with 5% SN of anti-CD3 Ab (145-
2C11), which induces maximum proliferation, in the presence of splenic APCs 
(3x10
4
/well), in 96-well round-bottomed plates in DMEM containing 10% heat-
inactivated FCS, penicillin (100 U/ml), streptomycin (100 g/ml), 2 mM L-glutamine, 
10 mM Hepes, 1 mM sodium pyruvate, and 50 M 2-ME.  In some experiments, instead 
of anti-CD3 Ab SN plus APC, anti-CD3 Ab- and anti-CD28 Ab-conjugated beads 
(1x10
4
/well, Dynal Biotech ASA, Oslo, Norway) were used to stimulate CD4 T cells.  
The proliferation of T cells (triplicate cultures) was assessed by measuring the 
incorporation of [
3
H]TdR (37kBq/well) for the final 4 h of a 3-day culture.   
 
Abs and reagents.   
The following Abs were used: anti-CD90 Abs (53-2.1, FF-10 and 30-H12), anti-
CD3 (145-2C11 or M-20), anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-CD45 (30-F11), 
anti-TCR (H57-597), anti-H-2Kb (AF6-88.5), anti-H-2Dd (34-2-12), anti-mouse IgM 
and anti-rat IgG, all purchased from BD PharMingen, Santa Cruz Biotechnology, 
eBioscience, Cell Signaling, or Abcam, and anti-CD90 Ab (HO-13-4) purchased from 
American Type Culture Collection.  The intracellular staining of mouse splenocytes 
with anti-Foxp3 Ab was performed with an anti-mouse Foxp3 staining set (eBioscience), 
according to the manufacturer’s directions.  After staining, cells were analyzed with 
FACSCanto II (BD Biosciences).  All Abs used for western-blotting experiments were 
purchased from Cell Signaling and Santa Cruz Biotechnology.  In some experiments, 





Preparation of mAbs.   









 T cells 1 month 
later.  Spleen cells were fused with P3X63Ag8.653 myeloma cells (from American 
Type Culture Collection) 3 days after the final immunization.  For details on the 
screening of the mAbs, see Results. 
 
Immunoprecipitation and Western blotting. 
Cells were washed and lysed in lysis buffer containing 50 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail (nacalai tesque, 
Japan).  After a 20-min incubation on ice and following centrifugation, the cell lysate 
was recovered and incubated with Ab-coupled Sepharose 4FF (Amersham Biosciences) 
for 100 min at 4°C.  After washing with lysis buffer three times, bound proteins were 
subjected to SDS-PAGE, blotted onto a membrane, and immunoblotted.  
 
Bone marrow chimeras. 
 Bone marrow from femurs and tibias was collected in DMEM, and single cell 
suspensions were prepared.  T cells and NK cells were eliminated using anti-CD4 
(RL172.4), anti-CD8 (3.155), and anti-NK1.1 (PK136) Abs and rabbit complement.  
Cells (2x10
6
) were then injected intravenously into -irradiated BALB/c mice (8.0 Gy, 
Gamma Cell 40 Exactor).  In some experimental groups, CD4 T cells (2x10
5
) negatively 





LP5 Ab can inhibit the activation of CD4 T cells.   
 To develop new mAbs for use as immunosuppressive agents, we first tried to 
establish mAbs having a suppressive effect on CD4 T cells through the functional 




 T cells of BALB/c 
mice, and the immunized spleen cells were fused with P3X63Ag8.653 myeloma cells.  





 T cells.  Hybridomas with stable anti-proliferative activity were 
subjected to subsequent cloning.  Finally, one clone [LP5 (rat IgM)] was established.  
LP5 Ab could inhibit the polyclonal and/or Ag-specific activation of CD4 T cells 
(Fig.1A and B), and the inhibition was LP5 Ab dose-dependent (Fig. 1C).  LP5 Ab itself 
had no stimulatory activity even in the presence of APCs.  Furthermore, it was indicated 
that LP5 Ab directly acted on CD4 T cells since CD4 T cells stimulated with anti-
CD3/CD28-coated beads were also inhibited by LP5 Ab (Fig. 1D).  It was also observed 
that LP5 inhibits a signaling cascade leading to T-cell activation (Fig. S1). 
 
LP5 Ab recognizes CD90.   
Next, we examined the distribution of target molecules recognized by LP5 Ab.  
Whole spleen cells were stained with anti-CD4 or anti-CD8 Ab, and LP5 Ab (Fig. S2A).  
Almost all CD4 T cells and all CD8 T cells were positive for LP5, and the staining 
intensity of LP5 Ab was slightly decreased on the activated T cells.  In addition, both 
Treg and non-Treg cells were positive for LP5 (Fig. S2B).  Mouse T cell leukemia cell 
lines (EL-4 and RLm1) were stained positively with LP5 Ab, and Meth A (mouse 
fibrosarcoma) was not (data not shown).  To identify the targets of LP5 Ab, first, cell-
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lysate was prepared from these three tumor cells, subjected to SDS-PAGE under non-
reducing conditions, transferred onto a membrane, and blotted with LP5 Ab.  Western 
blot analysis revealed that LP5 Ab recognized molecules of approximately 25 kDa (Fig. 
2A).  Under reducing conditions, LP5 Ab failed to detect the proteins.  Next, the lysate 
prepared from LP5-positive tumor cells was immunoprecipitated with LP5 Ab-beads, 
and the beads-bound proteins were analyzed.  As shown in Fig. 2B, a band of the same 
size was immunoprecipitated with LP5 Ab.  Then the single 25-kDa band in the silver-
stained gel was excised, treated with trypsin, and subjected to MALDI-TOF/mass 
spectrometry.  A database search revealed that this band contains a small GPI-anchored 
protein, Thy-1 (CD90).  To confirm whether LP5 Ab recognizes CD90, the proteins 
immunoprecipitated with LP5 Ab-beads were blotted with two different anti-CD90 Abs 
(FF-10 and 30-H12).  As shown in Fig. 2C and 2D, both anti-CD90 Abs detected the 25 
kDa molecule immunoprecipitated with LP5 Ab.  Furthermore, we performed a binding 
competition assay (Fig. 2E).  Staining of CD90-positive EL-4 tumor cells with anti-
CD90 Abs (53-2.1, 30-H12, and FF-10) was inhibited in the presence of the LP5 Ab 
with a somewhat different competitive efficiency.  Taken together, these results indicate 
that LP5 Ab recognizes the CD90 molecule. 
 
LP5 Ab induces the down-modulation of CD3 molecules.   
 It is reported that CD90 is involved in T cell activation [18]; some anti-CD90 
Abs in the context of co-stimulation cause the activation of mouse T cells.  For example, 
an anti-CD90 Ab, FF-10, can augment the activation of CD4 T cells stimulated with 
anti-CD3/CD28-beads or with anti-CD3 Ab in the presence of APCs, with some 
differences in efficiency (Fig. S3, A and B).  Another anti-CD90 Ab, HO-13-4, exhibits 
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a slightly suppressive effect, or almost no effect, on the activation of CD4 T cells (Fig. 
S3, C and D).  On comparing LP5 with these anti-CD90 Abs, we found that LP5 caused 
the down-regulation of CD3 expression at the cell surface.  By culturing whole spleen 
cells with LP5 for 1 h at 37
o
C, the majority of CD4 T cells lost their CD3 surface 
expression (Fig. 3A).  In contrast, the stimulatory anti-CD90 Ab, FF-10, had no effect 
on the staining intensity with anti-CD3 Ab.  The HO-13-4 Ab slightly reduced the 
staining with the anti-CD3 Ab.  In all cases with three different Abs, the staining with 
each anti-CD90 Ab itself exhibited no difference even after 1 h of culture (Fig. 3B).  
These results suggest that LP5 has no influence on the expression of CD90 molecules 
themselves, however, it induces the down-regulation of CD3, and that only a 
suppressive anti-CD90 Ab, LP5, induces this phenomenon.   
 Since the culture of purified CD4 T cells with LP5 resulted in the same decrease 
in CD3 (Fig. S4A), we confirmed that the direct action of the Ab on CD4 T cells is 
enough for this effect, with no requirement for other cells in the culture.  Furthermore, it 
was observed that the reduction in CD3 is caused by LP5, on the other hand, the anti-
CD3 Ab had no influence on the cell surface expression of CD90 (Fig. S4B).  In 
addition, the fixed cells retained CD3 on their surface even in the presence of LP5 (Fig. 
S4C).  Taken together, these results suggest that the diminished staining with the anti-
CD3 Ab after LP5 pre-treatment is not due to the competition between LP5 and the anti-
CD3 Ab.  This unique property of LP5 was observed not only on splenic CD4 T cells 
but also on other tissue (mesenteric, inguinal, axillary lymph nodes and Peyer’s patch)-
derived CD4 T cells (data not shown). 
 To investigate the kinetics of the reduction in CD3, splenic cells were cultured 
in the presence or absence of LP5 for various periods, washed, and stained with the anti-
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CD3 Ab (Fig. S5A).  The amount of CD3 decreased after just 15 min, with a peak 
reduction at 1-2 h, and then recovered almost to the basal level at 24 h.  The expression 
of CD90 was constant throughout the culture.  Biochemical experiments revealed the 
total amount of CD3 to be constant throughout the period of LP5 treatment, with some 
decrease after 0.5 hr (Fig. S5B).  We also examined the influence of the Ab on the 
expression of other T cell surface molecules (Fig. 3C).  In addition to CD3, TCR was 
affected by LP5.  Other molecules including CD4 and CD45 remained largely 
unchanged in their cell surface expression. 
 Next, we investigated whether the LP5-induced decrease in CD3 was associated 
with lipid rafts, where CD90 is reportedly located [19].  T cells were treated with LP5 in 
the presence or absence of methyl-β-cyclodextrin (MCD), which causes a depletion of 
membrane cholesterol [29,30].  Thirty minutes after the treatment, the decrease in CD3 
reached a maximum in the absence of MCD.  In contrast, in the presence of MCD, 
the effect of the Ab was inhibited significantly, and the majority of cells maintained an 
intermediate level of CD3 on the cell surface (Fig. 4A).  The presence of MCD had no 
influence on the staining with the anti-CD3 and LP5 Abs (data not shown).  These 
results suggest that the effects of LP5 on CD3 expression depend on the construction of 
lipid rafts. 
 We have shown that there is no competition between LP5 and the anti-CD3 Ab 
in staining (Fig. S4, B and C).  Some molecules expressed on the cell-surface are 
continuously recycled through endocytosis and exocytosis [26].  Therefore, we next 
examined whether LP5 has any effect on the recycling of CD3.  Cells were treated with 
LP5 under neutral or acidic conditions, which can inhibit endocytosis [29].  As shown 
in Fig. 4B, in the acidic culture, the reduction in CD3 caused by LP5 was dramatically 
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inhibited.  We confirmed that even in acidic conditions, the Ab could bind to CD90 
molecules without any loss of staining intensity (data not shown).  The results indicate 
that the LP5-mediated down-regulation is caused through accelerated endocytosis of 
CD3 molecules at the cell surface. 
  
Down-regulation of CD3 expression in the early stages of T cell-activation is 
critical to hyporesponsiveness. 
 We have shown that LP5 added to a culture continuously inhibited the activation 
of CD4 T cells (Fig. 1) and induced a temporal reduction in the expression of CD3 (Fig. 
S5A).  Then, we next investigated the relationship between the suppressive effect and 
decrease in CD3.  First, we examined whether the pre-treatment of CD4 T cells with 
LP5 is enough, or the continuous presence of the Ab is required, for the induction of 
hyporesponsiveness.  CD4 T cells were pre-treated with LP5 at 37
o
C for 90 min, 
washed three times, and stimulated with the anti-CD3 Ab along with APCs.  As shown 
in Fig. 5A and 5B, pre-treatment with LP5 for 90 min was enough to cause 
hyporesponsiveness in CD4 T cells.  In contrast, CD4 T cells pre-treated with LP5 for 
90 min, washed, then cultured in normal medium for an additional 28 h, or CD4 T cells 
pre-treated with LP5 for 28 h and washed, showed normal proliferation in the 
stimulation culture (Fig. 5C).  Furthermore, LP5 added in the late stages of a 3-day 
culture, but not in the initial stages, had no suppressive effect on CD4 T cell activation 
(Fig. 5D).  Taken together, these results indicate that a down-regulation of CD3 





The pre-treatment of CD4 T cells with LP5 Ab prolonged the survival of allogeneic 
grafts.   
 Pre-treatment of CD4 T cells with LP5 was effective in inducing 
hyporesponsiveness in vitro (Fig. 5).  Next, we investigated whether it is effective in 
vivo.  First, we examined whether the Ab bound to CD4 T cells is toxic in vivo.  To 
examine this possibility, BALB/c CD4 T cells pre-treated with LP5 were transferred 
into CB17.scid mice.  Two weeks later, splenic cells were harvested, and examined for 
the presence of CD4 T cells.  As shown in Fig. S6, the pre-treatment with LP5 had no 
significant toxic effect on CD4 T cells.  Then we investigated whether this pre-
treatment is effective in prolonging the graft’s survival.  To this end, we used a mouse 
model for bone marrow transplantation in which BALB/c hosts are lethally irradiated 
and reconstituted with a 1:1 mixture of BALB/c (H-2
d
) and CBF1 (H-2
dxb
) bone marrow 
[8].  Two weeks after the transfer, bone marrow cells were examined for the presence of 
syngeneic and semi-allogeneic cells.  When bone marrow cells alone were transferred, 
semi-allogeneic cells were detected (Fig. 6, circles).  However, when BALB/c CD4 T 
cells were co-transferred, the semi-allogeneic cells were eliminated, and some of the 
recipient mice died probably due to the reaction of co-transferred BALB/c CD4 T cells 
with CBF1 bone marrow cells (squares).  In contrast, when the co-transferred BALB/c 
CD4 T cells were pre-treated with LP5, we detected almost the same percentage of 
CBF1 bone marrow cells, and all recipient mice survived (triangles).  In another set of 
experiments, mice were monitored until day 38 after cell-transfer.  At this time point, 
we observed a decrease in the percentage of CBF1 cells, indicating that the pre-
treatment of CD4 T cells with LP5 is not enough for the complete survival of semi-
allogeneic cells, but enough for the prolongation of their survival.  Collectively, these 
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results suggest that CD3 down-modulation induced by in vitro pre-treatment with LP5 
is effective in preventing CD4 T cell activation in vivo. 
 
Discussion 
 CD90 expressed by mouse T cells has signal transduction properties [18,31].  
Studies using anti-CD90 Ab or CD90-deficient mice have proposed both stimulatory 
and inhibitory roles for CD90 [20-25].  For example, thymocytes from CD90-deficient 
mice were hyper-responsive to TCR-stimulation as demonstrated by cell proliferation 
[24].  CD90 cross-linking on T cells by an anti-CD90 Ab (21F10) inhibited T cell 
proliferation [32].  These reports suggest that CD90 functions as a negative regulator of 
TCR-mediated signaling.  In contrast, the majority of studies using anti-CD90 Abs 
demonstrated a mitogenic role for CD90 in T cell activation [22,25,31,33].  One anti-
Thy-1 Ab, clone G7, augmented TCR/CD28-driven T cell proliferation [33].  Another 
anti-CD90 Ab, 30-H12, had no potential to activate T cells, but, was able to block CD90 
signaling as a soluble form, resulting in inhibition of the anti-CD3-induced proliferation 
of CD4 T cells [33], suggesting an important co-stimulatory role for CD90 signaling in 
mouse T cell activation.  In this paper, we reported a new anti-CD90 Ab, LP5, which 
was established based on its suppressive activity against CD4 T cell activation.  This 
anti-CD90 Ab had the potential to prevent activation of CD4 T cells through a temporal 
down-regulation of CD3/TCR expression, which has not been reported previously for 
an anti-CD90 Ab.  Furthermore, we demonstrated that the down-regulation of 
TCR/CD3 complexes prior to, or during the early stages of, T cell activation results in T 
cell hypo-responsiveness, and effective in prolonging graft survival in vivo.  Moreover, 
LP5 caused this down-modulation without any induction of T cell activation.   
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It is known that TCR/CD3 complexes in resting T cells are internalized and 
recycled constitutively [26].  Once T cells are activated by antigens, down-modulation 
of TCR/CD3 complexes from the cell surface is induced [27].  In contrast to this 
naturally occurring reduction in TCR/CD3 upon T cell activation [27], the active down-
regulation of TCR/CD3 with the use of an anti-CD3 Ab is useful in regulating immune 
responses in mice and humans.  For example, it has been demonstrated that anti-CD3 
mAb therapy promotes remission of established type 1 diabetes mellitus [34,35].  As 
one mechanism leading to remission, it was proposed that the anti-CD3 Ab induces a 
capping of TCR/CD3 complexes at the cell surface and their internalization and/or 




 T cells) become transiently 
‘blind’ to antigens and unresponsive to stimulation.  However, at the same time, 
inoculation of the anti-CD3 Ab accompanied flu-like symptoms, linked to limited 
cytokine release in the early stages after treatment [36,37].  Because these side effects 
were associated with cross-linking of CD3 via an Fc-dependent mechanism, many kinds 
of anti-CD3 Abs were developed by modifying the Fc portion of the Abs to reduce FcR 
binding, which is critical to the stimulatory activity.  Nevertheless, they still promoted 
some degree of T cell activation and cytokine release [38,39].  Therefore, Abs, such as 
LP5, having the potential to down-modulate TCR/CD3 complex, and having no 
stimulatory properties regarding T cells, would be useful in regulating immune 
responses.   
 We showed that an anti-CD90 Ab, LP5 (rat ), could down-regulate the 
expression of CD3/TCR complexes.  As shown in Fig. 3A, this property was not 
observed among other anti-CD90 Abs, FF-10 (rat 2c) and HO-13-4 (mouse ).  In 
another experiment, we also investigated whether other anti-CD90 Abs have this 
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potential; 30-H12 (rat 2b) and 53-2.1 (rat 2a) (both used at 1 g/ml) had no effect on 
CD3 expression; J1j.10 (rat ) and M5/49.4.1 (rat 2a) (both at 50% SN) induced a 
reduction in CD3 but less effectively than LP5 (rat ).  These results suggest that the 
properties of LP5 are not dependent on its Ig-subclass.  LP5 could compete with other 
anti-CD90 Abs in staining (Fig. 2E), however, it might recognize a unique determinant 
on the CD90 molecule, which would be critical for the induction of CD3/TCR down-
modulation.  Taken together, LP5 would be appropriate for controlling TCR/CD3 
complexes without any stimulatory effect on CD4 T cells.  However, we also need to 
consider that a ligand or counter-receptor for mouse CD90 has not yet been identified 
[18].  In addition, CD90 is expressed on almost all peripheral T cells in mice, but in 
humans, it was expressed only on a small percentage of thymocytes, and <1% of CD3
+
 
lymphocytes in the peripheral circulation.  Therefore, seeking a new Ab against target 
molecules on the cell-surface, which induces a reduction in TCR/CD3 and has no 
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 T cells from DO11.10 mice were cultured with APCs plus the titrated 
amount of anti-CD3 Ab (A) or OVA323-339 peptide (B) in the presence (open symbol) or 





 T cells from BALB/c mice were cultured with anti-CD3 Ab (5% 
SN) plus APCs (C), or anti-CD3 Ab/anti-CD28 Ab-coated beads (D) in the presence 
(open) or absence (closed) of the titrated amount of LP5 Ab.  Data are representative of 
more than five independent experiments. 
 
Figure 2  LP5 recognizes CD90.  (A) Total cell lysate from the indicated tumor 
cells was subjected to SDS-PAGE under non-reducing conditions, transferred onto a 
membrane, blotted with LP5, and visualized.  (B) The lysate was immunoprecipitated 
(IP) with LP5 Ab- or Rat IgG-coated beads.  The beads-bound proteins were subjected 
to SDS-PAGE under non-reducing conditions and western-blotted with LP5.  (C and D) 
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The proteins immunoprecipitated by LP5-beads were treated as in (A), then blotted with 
anti-CD90 Abs [FF-10 (C) or 30-H12 (D)].  (A-D) The arrow indicates a molecular 
weight of 25 kDa.  (E) EL-4 tumor cells were pre-treated with (green) or without (red) 
LP5, and then stained with the indicated anti-CD90 Abs.  Negative control staining is 
shown as a black line.  Data are representative of more than three (A-E) independent 
experiments. 
 
Figure 3  LP5 induces down-regulation of CD3 expression.  (A and B) BALB/c 
whole spleen cells were cultured at 37 
o
C in the presence (green line) or absence (red) of 
the Ab LP5 (rat , 50% SN), FF-10 (rat 2c, 10 g/ml), or HO-13-4 (mouse , 50% SN) 
as indicated.  Sixty minutes later, cells were harvested, washed, and stained with anti-
CD4 and anti-CD3 (A) or anti-rat or mouse Ig Ab (B).  All CD4
+
 cells were analyzed 
for CD3 (A) or CD90 (B) staining.  (C) Spleen cells were pre-treated with LP5 (bottom 
panels) or medium (top) for 60 min at 37
o
C, washed, and stained with the indicated Abs 
(green) and anti-CD4 Ab.  Negative control staining is shown as a red line.  The 
expression of the indicated molecules on CD4 T cells is shown as a histogram.  Data are 
representative of more than two (A and B) or three (C) independent experiments.  
 
Figure 4 LP5 can influence the internalization of CD3.  (A) BALB/c spleen 
cells were washed with FCS-free medium, and pre-cultured with or without MCD (1 
mM) at 37
o
C.  Ten minutes later, the cells were cultured in the presence (green lines) or 
absence (red) of LP5 for 30 min, washed, and stained with anti-CD3 and anti-CD4 Ab.  
All CD4
+
 T cells were analyzed for CD3 staining.  (B) Splenic cells were suspended in 
neutral or acidic medium (40 mM acetic acid) for 5 min at 37
o
C, treated with (green) or 
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without (red) LP5 for 30 min, washed, stained and analyzed as in (A).  We confirmed 
that even in the presence of MCD (A), or under acidic conditions (B), LP5 could bind 
to CD90 without any decrease in staining intensity (data not shown).  Data are 
representative of more than three independent experiments. 
 
Figure 5 Pre-treatment of CD4 T cells with LP5 is enough for 
hyporesponsiveness.  (A) CD4 T cells were pre-treated with LP5 Ab for 90 min, 
washed three times, and then cultured with the anti-CD3 Ab along with APCs.  Three 
days later, cell proliferation was measured.  The proliferation of the pre-treated T cells 
was compared with that of untreated T cells, and expressed as % response.  Each 
symbol represents individual preparations of pre-treated T cells.  (B) CD4 T cells 
untreated (circle) or pre-treated with LP5 (square), as in (A), were cultured with the 
titrated amount of anti-CD3 Ab SN along with APCs.  (C) CD4 T cells cultured in 
medium (circle) or LP5 (triangle) for 28 h, or CD4 T cells pre-treated with LP5 for 90 
min, washed, and cultured in medium for an additional 26 h (square), were washed, and 
cultured with the titrated amount of anti-CD3 Ab along with APCs.  (D) CD4 T cells 
were stimulated with the anti-CD3 Ab in the presence of APCs, and at the indicated 
time points during a 3-day culture, LP5 (25% SN) or medium was added to the culture.  
Three days later, cell proliferation was measured.  Data are representative of two to 
three independent experiments (B-D). 
 
Figure 6  Pre-treatment of CD4 T cells with LP5 prolonged the survival of 
allogeneic grafts.  Both bone marrow cells (1:1 ratio) from BALB/c and CBF1 mice 
were transferred into -irradiated BALB/c mice (circle).  At the same time, untreated 
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(square) or LP5-treated CD4 T cells (triangle) from BALB/c mice were co-transferred.  
The survival of each recipient mouse was monitored (lower panels).  At the end of the 









 -positive cells (semi-




 cells was calculated as follows: (% of semi-
allogeneic cells in experimental mouse / mean % of semi-allogeneic cells in mice 
injected with bone marrow cells only) x 100.  Each symbol represents an individual 
mouse.  Combined data from two independent experiments are shown in left panels, 
whereas right panels represent a single experiment. 
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Effect of LP5 on signaling molecules associated with T cell activation.
CD4 T cells purified by negative selection were treated with or without LP5 (50% SN) for 90 min at 37oC, 
and then anti-CD3 Ab (2C11, hamster IgG), anti-CD28 Ab (clone 37.51, hamster IgG), and finally anti-
hamster IgG Ab was added.  After the indicated period, cell lysate was prepared, subjected to SDS-PAGE 
under reducing conditions, transferred onto a membrane, blotted with the indicated Ab, and visualized.  Data 
are representative of three independent experiments.
We examined signaling molecules implicated in TCR-driven T cell activation, and whether they are 
influenced by LP5 (Fig. S1).  Zap-70 is activated following TCR stimulation.  In accordance with this, the 
activation of Zap-70, that is, an increase in phosphorylated Zap-70 (Tyr319), was evident by 5 min post-
stimulation with the anti-CD3 and anti-CD28-Abs.  However, by pre-treating cells with LP5 for 90 min, 
phosphorylation of Zap-70 (Tyr319) was inhibited; no increase in p-Zap-70 (Tyr319) at any time-point 
examined.  Furthermore, phosphorylation of Akt and Erk, both required for the activation of T cells, was also 
significantly inhibited by the Ab.  Taken together, these results demonstrate that LP5 inhibits normal signal 





























Antigen recognized by LP5 is expressed on almost all T cells.  
(A) BALB/c spleen cells freshly prepared (naïve) or activated with anti-CD3 Ab for two days (activated) 
were stained with LP5 and anti-CD4 or anti-CD8.  (B) Naïve spleen cells were stained with LP5, anti-CD4, 
and anti-Foxp3.  The expression of LP5-target molecules on CD4+Foxp3- (green) or CD4+Foxp3+ (red) cells 




























































Figure S3  
Effect of anti-CD90 Abs, FF-10 and HO-13-4, on the activation of CD4 T cells.  
BALB/c CD4+CD25- T cells were cultured with anti-CD3/anti-CD28 Ab-coated beads (A and C) or anti-
CD3 Ab (5% SN) along with APCs (B and D) in the presence (open symbols) of titrated amount of FF-10 Ab 
(upper panels) or HO-13-4 Ab (lower panels).  As a control, cells were cultured in the absence of anti-CD90 


























Figure S4  
Characterization of LP5-induced decrease in CD3.  
(A) BALB/c whole spleen cells or CD4 T cells purified by negative selection were treated with LP5 (green) 
or medium (red) for 60 min, washed, and stained with anti-CD4 and anti-CD3 Abs.  The expression of CD3 
in CD4 T cells is shown as a histogram.  (B) Purified splenic CD4 T cells were cultured, as in (A), in the 
presence of LP5 (top panel, green) or anti-CD3 Ab (bottom, green), then stained with anti-CD3 or anti-CD90 
Ab, respectively.  As a control, cells were cultured in the absence of Abs (red).  (C) Purified CD4 T cells 
were treated with or without 1% paraformaldehyde (Fix), washed, treated with LP5 (green) or medium (red), 
and stained with anti-CD3 Ab.  We confirmed that the fixed cells could be stained with LP5 without any 













































LP5 induces a temporary decrease in CD3.
(A) BALB/c spleen cells were cultured for the indicated period with (green) or without (red) LP5, and then 
stained with anti-CD4 and anti-CD3 Ab or anti-rat Ig Ab.  All CD4+ T cells were analyzed for CD3 (left 
panels) or CD90 (right panels) staining.  (B) Purified CD4 T cells from BALB/c mice were treated with LP5 
(50% SN) at 37oC.  After the indicated period (hours), cell lysate was prepared, and examined for the 
existence of CD3e, as in Fig. S1.  As a control, the amount of tubulin was also examined.  Optical density 
ratios (indicated in the bottom) were calculated by comparing the density of individual CD3e bands with the 















The pre-treatment of BALB/c CD4 T cells with LP5 has no cytotoxic effect in vivo.
CD4 T cells prepared from BALB/c mice were pre-treated with LP5, washed three times, and transferred 
intravenously into CB17.scid mice (9x105/mouse).  Fourteen days later, splenic cells were stained with anti-
CD4 Ab, and examined for the remaining CD4 T cells (triangle).  As a control, untreated CD4 T cells were 
transferred (circle).  Each symbol represents an individual recipient.  Statistical significance of the difference 
between untreated (6.9 ± 1.9 %) and LP5-treated (5.1 ± 1.4 %): p=0.127.  
